Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Irritation and Sensitization Potential of a Selegiline Transdermal Delivery System (6 mg/24 h) as Compared to a Reference Product (EMSAM® 6 mg/24 h)

NCT07452692 is registered in ClinicalTrials.gov with Corium Innovations, Inc. as lead sponsor.

NCT NCT07452692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07452692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Irritation and Sensitization Potential of a Selegiline Transdermal Delivery System (6 mg/24 h) as Compared to a Reference Product (EMSAM® 6 mg/24 h)
Lead sponsor
Corium Innovations, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 23, 2026
Completion date
October 13, 2026
Enrollment
232 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)